KRAS G12-MUTANT NSCLC

Clinical trials for KRAS G12-MUTANT NSCLC explained in plain language.

Never miss a new study

Get alerted when new KRAS G12-MUTANT NSCLC trials appear

Sign up with your email to follow new studies for KRAS G12-MUTANT NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Experimental cancer pill shows promise in early trial

Disease control Terminated

This early-stage study tested an experimental oral drug called TNO155 in 227 adults with advanced solid tumors (like lung, skin, or esophageal cancer) that had stopped responding to standard treatments. The main goal was to find safe doses and understand side effects, both when g…

Matched conditions: KRAS G12-MUTANT NSCLC

Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated May 14, 2026 12:04 UTC

KRAS G12-MUTANT NSCLC

Get alerted when new KRAS G12-MUTANT NSCLC trials appear

Experimental cancer pill shows promise in early trial